CMRA - Comera Life Sciences Holdings, Inc. Stock Price, Fair Value and News

Market Closed

CMRA Stock Valuation Analysis

Valuation

Max Portfolio %

CMRA Price Action

CMRA RSI Chart

CMRA Stock Valuation Analysis

Valuation

Max Portfolio %

CMRA Valuation

CMRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CMRA Fundamentals

CMRA Revenue

CMRA Earnings

CMRA Profitability

CMRA Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	930.7K	1.1M	1.0M	0
2022	327.4K	403.2K	550.3K	633.1K
2021	0	401.9K	360.9K	319.8K
2020	0	0	0	442.9K

Get all data in R, Python etc through our Historical Stock Data APIs

About Comera Life Sciences Holdings, Inc.

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

CEO	Mr. Jeffrey S. Hackman
WEBSITE	https://comeralifesciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	12